vTv Therapeutics (VTVT) Non-Current Deffered Revenue (2017 - 2026)

vTv Therapeutics has disclosed Non-Current Deffered Revenue across 10 years of filings, most recently posting $1.8 million for Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $1.8 million, down 90.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (down 90.2% YoY), and the FY2025 annual result was $18.7 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue came in at $1.8 million for Q1 2026 at vTv Therapeutics, down from $18.7 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $18.7 million in Q2 2022 to a low of $1.8 million in Q1 2026.
• The 5-year median for Non-Current Deffered Revenue is $18.7 million (2022), against an average of $17.6 million.
• Across the five-year window, Non-Current Deffered Revenue soared 207333.33% in 2022 and tumbled 90.2% in 2026, its largest moves.
• vTv Therapeutics' Non-Current Deffered Revenue stood at $18.7 million in 2022, then changed by 0.0% to $18.7 million in 2023, then changed by 0.0% to $18.7 million in 2024, then changed by 0.0% to $18.7 million in 2025, then sank by 90.2% to $1.8 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $1.8 million (Q1 2026), $18.7 million (Q4 2025), and $18.7 million (Q3 2025), per Business Quant data.